Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee - 47 ABC - Delmarva's Choice

Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Syndax Pharmaceuticals, Inc.

WALTHAM, Mass., Jan. 23, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its board of directors as an independent director and chairman of the audit committee. Mr. Shea is an experienced biotechnology executive with wide ranging experience in finance and operations as well as managing venture financings, initial public offerings, secondary offerings and mergers and acquisitions.

Mr. Shea is currently senior vice president and chief financial officer of Momenta Pharmaceuticals, Inc. where he managed a Series C venture round and various public offerings, including Momenta's initial public offering, which have raised over $300 million. Mr. Shea has also served as chief operating officer and chief financial officer at Variagenics, Inc. where he closed and managed the merger with Hyseq Pharmaceuticals, Inc. and managed a mezzanine financing and the company's $80 million initial public offering.

"We are fortunate to have someone with Rick's financial and business experience joining our board at a critical time in Syndax's development," said Dennis Podlesak, chairman of Syndax's board of directors. "Rick's experience will be indispensable to Syndax as it prepares to begin the Phase 3 study of entinostat in women with ER+ metastatic breast cancer in the first half of this year."

Prior to Variagenics, Mr. Shea was vice president, finance at Genetics Institute, LLC where he oversaw the growth of the company's annual revenues from $88 million to more than $400 million while the company grew from 600 employees to over 1,600. Mr. Shea holds a bachelor's degree from Princeton University and an MBA from the Public Management Program at Boston University.

About Syndax Pharmaceuticals

Syndax is developing entinostat for the treatment of patients with therapy-resistant cancers. Entinostat is designed to prolong the effectiveness of current cancer treatments through an epigenetic mechanism and has been designated a Breakthrough Therapy by the FDA when used in combination with exemestane in ER+ metastatic breast cancer. The company holds worldwide rights to entinostat, an oral, selective HDAC inhibitor that is expected to be evaluated in combination with exemestane in a pivotal Phase 3 clinical study for the treatment of ER+ metastatic breast cancer.

Corporate Contact:
Bob Goodenow
Chief Business Officer
Syndax Pharmaceuticals
(781) 419-1418
BGoodenow@Syndax.com

Media Contacts:
David Schull or Matt Middleman, M.D.
Russo Partners
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com

©2012 PR Newswire. All Rights Reserved.

  • HealthMore>>

  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
  • Spouse's sunny outlook may be good for your health

    Spouse's sunny outlook may be good for your health

    Marriage vows often include the promise to stick together for better or for worse, and research now suggests that when it comes to your health, having an optimistic spouse is better.More >>
    Marriage vows often include the promise to stick together for better or for worse, and research now suggests that when it comes to your health, having an optimistic spouse is better.More >>
  • Mental illness not a driving force behind crime

    Mental illness not a driving force behind crime

    TUESDAY, April 22, 2014 (HealthDay News) -- Less than 10 percent of crimes committed by mentally ill people are directly linked to the symptoms of their disorders, a new study shows. "When we hear about crimes committed by people with mental illness, they tend to be big headline-making crimes, so they get stuck in people's heads," said study author Jillian Peterson, a psychology professor at Normandale Community College in Bloomington, Minn. "The vast majority of people with mental illness a...More >>
    TUESDAY, April 22, 2014 (HealthDay News) -- Less than 10 percent of crimes committed by mentally ill people are directly linked to the symptoms of their disorders, a new study shows. "When we hear about crimes committed by people with mental illness, they tend to be big headline-making crimes, so they get stuck in people's heads," said study author Jillian Peterson, a psychology professor at Normandale Community College in Bloomington, Minn. "The vast majority of people with mental illness a...More >>
Powered by WorldNow
Powered by WorldNow All content © Copyright 2000 - 2014 WorldNow and WMDT. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.